260 related articles for article (PubMed ID: 19811373)
1. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis.
Chapman KR; Stockley RA; Dawkins C; Wilkes MM; Navickis RJ
COPD; 2009 Jun; 6(3):177-84. PubMed ID: 19811373
[TBL] [Abstract][Full Text] [Related]
2. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.
Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N
Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.
Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
Eur Respir J; 1998 Feb; 11(2):428-33. PubMed ID: 9551749
[TBL] [Abstract][Full Text] [Related]
4. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.
Am J Respir Crit Care Med; 1998 Jul; 158(1):49-59. PubMed ID: 9655706
[TBL] [Abstract][Full Text] [Related]
5. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
6. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society.
Abboud RT; Ford GT; Chapman KR;
Can Respir J; 2001; 8(2):81-8. PubMed ID: 11320399
[TBL] [Abstract][Full Text] [Related]
7. Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry.
Rahaghi FF; Monk R; Ramakrishnan V; Beiko T; Strange C
Int J Chron Obstruct Pulmon Dis; 2020; 15():3193-3199. PubMed ID: 33299307
[TBL] [Abstract][Full Text] [Related]
8. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
Campos MA; Lascano J
Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223
[TBL] [Abstract][Full Text] [Related]
9. Augmentation therapy for alpha-1 antitrypsin deficiency--not enough evidence to support its use yet!
McCarthy C; Dimitrov BD
COPD; 2010 Jun; 7(3):234; author reply 235-6. PubMed ID: 20486824
[No Abstract] [Full Text] [Related]
10. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.
Stoller JK; Fallat R; Schluchter MD; O'Brien RG; Connor JT; Gross N; O'Neil K; Sandhaus R; Crystal RG
Chest; 2003 May; 123(5):1425-34. PubMed ID: 12740257
[TBL] [Abstract][Full Text] [Related]
11. Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis.
Fraughen DD; Ghosh AJ; Hobbs BD; Funk GC; Meischl T; Clarenbach CF; Sievi NA; Schmid-Scherzer K; McElvaney OJ; Murphy MP; Roche AD; Clarke L; Strand M; Vafai-Tabrizi F; Kelly G; Gunaratnam C; Carroll TP; McElvaney NG
Am J Respir Crit Care Med; 2023 Nov; 208(9):964-974. PubMed ID: 37624745
[No Abstract] [Full Text] [Related]
12. ICS Use May Modify FEV1 Decline in α1-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils.
Low EV; Hughes SM; Zaffarullah S; Kantas D; Stockley RA; Turner AM
Respiration; 2018; 95(2):114-121. PubMed ID: 29253843
[TBL] [Abstract][Full Text] [Related]
13. [Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].
Wencker M; Banik N; Buhl R; Seidel R; Konietzko N
Pneumologie; 1998 Oct; 52(10):545-52. PubMed ID: 9847632
[TBL] [Abstract][Full Text] [Related]
14. Augmentation therapy in alpha-1 antitrypsin deficiency.
Sandhaus RA
COPD; 2009 Jun; 6(3):147-8. PubMed ID: 19811367
[No Abstract] [Full Text] [Related]
15. Alpha1-antitrypsin deficiency: forgotten etiology.
Kaplan A; Cosentino L
Can Fam Physician; 2010 Jan; 56(1):19-24. PubMed ID: 20090075
[TBL] [Abstract][Full Text] [Related]
16. The role of augmentation therapy in alpha-1 antitrypsin deficiency.
Kueppers F
Curr Med Res Opin; 2011 Mar; 27(3):579-88. PubMed ID: 21226542
[TBL] [Abstract][Full Text] [Related]
17. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.
Gøtzsche PC; Johansen HK
Cochrane Database Syst Rev; 2010 Jul; (7):CD007851. PubMed ID: 20614465
[TBL] [Abstract][Full Text] [Related]
18. Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis.
Campos MA; Runken MC; Davis AM; Johnson MP; Stone GA; Buikema AR
Adv Ther; 2018 Apr; 35(4):467-481. PubMed ID: 29616482
[TBL] [Abstract][Full Text] [Related]
19. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
20. Alpha-1-antitrypsin replacement therapy: current status.
Abusriwil H; Stockley RA
Curr Opin Pulm Med; 2006 Mar; 12(2):125-31. PubMed ID: 16456382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
